Constantine Gennatas
Overview
Explore the profile of Constantine Gennatas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
77
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Poulou L, Thanos L, Ziakas P, Merikas E, Achimastos A, Gennatas C, et al.
J BUON
. 2017 Jul;
22(3):673-678.
PMID: 28730773
Purpose: Local thermal ablation may extend the scope of palliative therapy in patients with colorectal liver metastasis. We performed a retrospective, case-controlled study to compare patients with colorectal liver metastases...
2.
Gennatas C, Michalaki V, Kairi P, Kondi-Paphiti A, Voros D
World J Surg Oncol
. 2012 Sep;
10:181.
PMID: 22943457
Perivascular epithelioid cell tumor (PEComa) is an extremely rare neoplasm that appears to arise most commonly at visceral (especially gastrointestinal and uterine), retroperitoneal, and abdominopelvic sites. Malignant PEComas exist but...
3.
Michalaki V, Gennatas C
J Med Case Rep
. 2012 Apr;
6:115.
PMID: 22524151
Introduction: Chromophobe renal cell carcinoma is universally accepted as a distinct subtype of renal cell carcinoma. There are conflicting reports on prognosis, and few data on response to treatment exist....
4.
Michalaki V, Fotiou S, Gennatas S, Gennatas C
Anticancer Res
. 2010 Aug;
30(7):3051-4.
PMID: 20683054
Unlabelled: In human epidermal growth factor 2 (HER-2)-positive advanced breast cancer, taxanes plus trastuzumab are among the most widely applied options in the first-line setting. The addition of capecitabine to...
5.
Michalaki V, Arkadopoulos N, Kondi-Pafiti A, Gennatas C
World J Surg Oncol
. 2010 May;
8:45.
PMID: 20507643
Background: Renal cell carcinoma (RCC) represents approximately 3% of all adult cancers and is more common in males. Systemic treatment for RCC has improved following the introduction of tyrosine kinase...
6.
Gennatas C, Michalaki V, Gennatas S
Rev Recent Clin Trials
. 2009 Jan;
4(1):1-11.
PMID: 19149758
Capecitabine has been developed as a prodrug of FU, with the goal of improving tolerability and intratumor drug concentration through tumor-specific conversion to the active drug. The purpose of this...
7.
Argyriou P, Zisis C, Alevizopoulos N, Kefaloyannis E, Gennatas C, Petraki C
World J Surg Oncol
. 2008 Dec;
6:134.
PMID: 19091123
Background: Adrenal cortex oncocytic carcinoma (AOC) represents an exceptional pathological entity, since only 22 cases have been documented in the literature so far. Case Presentation: Our case concerns a 54-year-old...
8.
Gennatas C, Michalaki V, Mouratidou D, Tsavaris N, Andreadis C, Psychogios J, et al.
Anticancer Res
. 2006 Jun;
26(1B):549-52.
PMID: 16739318
Purpose: To evaluate the activity and toxicity of gemcitabine and vinorelbine in patients with metastatic breast cancer (MBC), previously treated with anthracyclines alone or with taxanes. Patients And Methods: A...
9.
Gennatas C, Michalaki V, Carvounis E, Psychogios J, Poulakaki N, Katsiamis G, et al.
Tumori
. 2006 May;
92(1):13-7.
PMID: 16683378
Aims And Background: The understanding of hormonal therapies in postmenopausal women with metastatic breast cancer has advanced greatly in the past several decades. With the introduction of orally active, potent...
10.
Gennatas C, Michalaki V, Mouratidou D, Tsavaris N, Andreadis C, Photopoulos A, et al.
In Vivo
. 2006 Apr;
20(2):301-5.
PMID: 16634534
Background: Gemcitabine is an active agent in pancreatic cancer, showing clinical synergy with 5-fluorouracil (5-FU). The aim of the study was to evaluate the safety and efficacy of the combination...